Clinic
The Griffin Hospital
The Griffin Hospital was paid $80.66M by Medicaid between Jan 2018 and Dec 2024, across 482 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoTHE GRIFFIN HOSPITAL
DERBY, CT 06418
DERBY, CT 06418
33aNPI1184639973assigned 07/30/2006
33bProvider typeEmergency Care Clinic/Center
28Total paid$80.66M
24GClaims2,343,766
24DCodes billed482
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in Connecticut
Rank by total paid#4 of 6
Median peer was paid$80.66M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 240,902 | $9.21M | |
| 2019 | 243,209 | $9.67M | |
| 2020 | 293,058 | $9.29M | |
| 2021 | 479,071 | $14.10M | |
| 2022 | 421,479 | $13.48M | |
| 2023 | 375,209 | $13.00M | |
| 2024incomplete | 290,838 | $11.90M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 36,977 | 31,444 | $14.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 22,890 | 19,090 | $11.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 38,414 | 33,587 | $8.07M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.0% | 25,035 | 18,890 | $3.24M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 130,810 | 59,916 | $3.16M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 57,509 | 15,220 | $2.80M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 7,070 | 6,248 | $1.46M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 2,753 | 2,561 | $1.37M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.7% | 1,689 | 1,605 | $1.36M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.6% | 1,851 | 1,709 | $1.26M |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 1.5% | 9,029 | 1,438 | $1.20M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.5% | 14,705 | 12,341 | $1.19M |
470 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 18,612 | $1.11M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 4,738 | $1.08M |
| S9480 | Intensive outpatient psychiatric services, per diem | 1.3% | 8,522 | $1.04M |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 17,128 | $927K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 7,795 | $825K |
| 95811 | 1.0% | 1,063 | $811K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,186 | $780K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,423 | $760K |
| 97010 | <1% | 11,963 | $741K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,935 | $706K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 64,363 | $697K |
| J9312 | Injection, rituximab, 10 mg | <1% | 138 | $591K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,657 | $556K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 739 | $490K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 24,621 | $474K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,562 | $434K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 24,444 | $409K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,876 | $406K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 40,981 | $406K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 24,775 | $383K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 570 | $378K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 3,559 | $376K |
| 80053 | Comprehensive metabolic panel | <1% | 99,372 | $366K |
| 76641 | <1% | 3,940 | $350K | |
| 0001A | <1% | 10,977 | $348K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 128,380 | $338K |
| J9310 | Injection, rituximab, 100 mg | <1% | 69 | $314K |
| 0002A | <1% | 9,286 | $309K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,206 | $307K |
| 80061 | Lipid panel | <1% | 34,282 | $306K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 7,560 | $303K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,902 | $287K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,323 | $286K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,555 | $282K |
| 76536 | <1% | 3,675 | $280K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 338 | $273K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,319 | $266K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,162 | $246K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,899 | $242K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,898 | $241K |
| 86900 | <1% | 5,315 | $236K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 404 | $217K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 12,317 | $211K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,747 | $209K |
| 36415 | Collection of venous blood by venipuncture | <1% | 185,564 | $186K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,126 | $180K |
| 77065 | Tomosynthesis, mammo | <1% | 1,634 | $178K |
| 77066 | Tomosynthesis, mammo | <1% | 1,581 | $177K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29,908 | $173K |
| 94060 | <1% | 1,010 | $173K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,218 | $167K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,200 | $167K |
| 76775 | <1% | 2,816 | $167K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,348 | $166K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 26,819 | $166K |
| 50590 | <1% | 63 | $165K | |
| 0071A | <1% | 4,853 | $163K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,655 | $149K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,349 | $147K |
| 76642 | <1% | 2,252 | $141K | |
| 93971 | <1% | 2,107 | $137K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,419 | $135K |
| 82607 | <1% | 14,481 | $131K | |
| 71250 | <1% | 2,480 | $129K | |
| 0072A | <1% | 3,704 | $128K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 31,267 | $123K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 3,353 | $119K |
| 0004A | <1% | 3,362 | $114K | |
| 94726 | <1% | 1,852 | $113K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,723 | $111K |
| 0054A | <1% | 3,270 | $110K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 860 | $105K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,671 | $103K |
| 0064A | <1% | 3,082 | $100K | |
| 97161 | <1% | 5,324 | $98K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,620 | $96K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,416 | $88K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,824 | $88K |
| 87481 | <1% | 1,479 | $84K | |
| 72100 | <1% | 1,963 | $83K | |
| 80074 | <1% | 2,890 | $82K | |
| 84439 | <1% | 15,129 | $81K | |
| 88142 | <1% | 6,247 | $79K | |
| 0012A | <1% | 2,584 | $79K | |
| 71271 | <1% | 768 | $79K | |
| 93017 | <1% | 1,322 | $77K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,892 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 30,053 | $74K |
| 87799 | <1% | 901 | $73K | |
| 73564 | <1% | 1,885 | $72K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 374 | $72K |
| 93798 | <1% | 1,374 | $69K | |
| 0011A | <1% | 2,334 | $67K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12,324 | $66K |
| 77080 | <1% | 655 | $65K | |
| 72110 | <1% | 1,445 | $63K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,178 | $58K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12,077 | $57K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,296 | $55K |
| 97165 | <1% | 972 | $55K | |
| 84480 | <1% | 6,132 | $55K | |
| 73030 | <1% | 3,065 | $52K | |
| 81513 | <1% | 549 | $52K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,593 | $51K |
| 86803 | <1% | 6,213 | $51K | |
| 82728 | <1% | 6,073 | $50K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,484 | $49K |
| 96415 | <1% | 528 | $48K | |
| 93970 | <1% | 388 | $48K | |
| 0124A | <1% | 1,374 | $47K | |
| 86480 | <1% | 1,299 | $47K | |
| 83970 | <1% | 2,292 | $47K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,982 | $43K |
| 84153 | <1% | 3,322 | $42K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,280 | $40K |
| 82746 | <1% | 4,665 | $40K | |
| 73610 | <1% | 2,778 | $40K | |
| 73630 | <1% | 2,925 | $39K | |
| 97116 | <1% | 4,734 | $39K | |
| 73110 | <1% | 1,919 | $38K | |
| 86769 | <1% | 1,054 | $37K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 286 | $36K |
| 84403 | <1% | 1,924 | $36K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 751 | $33K |
| 97113 | <1% | 561 | $33K | |
| 73562 | <1% | 1,958 | $33K | |
| 72141 | <1% | 210 | $32K | |
| 99221 | <1% | 730 | $30K | |
| 70486 | <1% | 710 | $30K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 711 | $29K |
| 87660 | <1% | 1,900 | $29K | |
| 83550 | <1% | 5,547 | $29K | |
| 87480 | <1% | 1,900 | $29K | |
| 87510 | <1% | 1,900 | $29K | |
| 82670 | <1% | 1,357 | $29K | |
| 97597 | <1% | 252 | $28K | |
| 74018 | <1% | 1,774 | $27K | |
| 83516 | <1% | 1,494 | $27K | |
| 0134A | <1% | 789 | $26K | |
| 83540 | <1% | 6,598 | $25K | |
| 87186 | <1% | 6,658 | $25K | |
| 73502 | <1% | 1,776 | $25K | |
| 73130 | <1% | 2,365 | $24K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 19,558 | $24K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,808 | $24K |
| 0051A | <1% | 669 | $24K | |
| 97035 | <1% | 353 | $23K | |
| 86696 | <1% | 1,583 | $23K | |
| 83001 | <1% | 1,628 | $23K | |
| 81001 | <1% | 29,749 | $23K | |
| 87512 | <1% | 670 | $23K | |
| 87070 | <1% | 4,964 | $23K | |
| 72050 | <1% | 387 | $23K | |
| 84702 | <1% | 5,194 | $22K | |
| 0052A | <1% | 590 | $21K | |
| 83880 | <1% | 4,915 | $21K | |
| 86592 | <1% | 5,898 | $20K | |
| 86003 | <1% | 312 | $20K | |
| 73140 | <1% | 590 | $19K | |
| 87077 | <1% | 5,550 | $19K | |
| 80076 | <1% | 6,662 | $19K | |
| 83735 | <1% | 13,308 | $18K | |
| 70496 | <1% | 89 | $18K | |
| 86038 | <1% | 2,468 | $18K | |
| 84146 | <1% | 1,602 | $18K | |
| 87625 | <1% | 728 | $17K | |
| 83655 | <1% | 1,583 | $17K | |
| 82570 | <1% | 6,193 | $16K | |
| G0378 | Hospital observation service, per hour | <1% | 9,722 | $16K |
| 97166 | <1% | 281 | $16K | |
| 95806 | <1% | 116 | $16K | |
| 84402 | <1% | 833 | $15K | |
| 86140 | <1% | 6,137 | $15K | |
| 87081 | <1% | 5,784 | $15K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 525 | $15K |
| 82043 | <1% | 4,422 | $15K | |
| 84144 | <1% | 1,042 | $14K | |
| 86618 | <1% | 1,641 | $14K | |
| 85651 | <1% | 7,377 | $14K | |
| 85610 | <1% | 16,959 | $13K | |
| 77062 | <1% | 895 | $13K | |
| 87631 | <1% | 630 | $13K | |
| 86376 | <1% | 1,514 | $13K | |
| 72040 | <1% | 550 | $13K | |
| 86800 | <1% | 1,290 | $13K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,261 | $12K |
| 73221 | <1% | 61 | $11K | |
| 97162 | <1% | 1,502 | $11K | |
| 73080 | <1% | 555 | $11K | |
| 87340 | <1% | 2,959 | $10K | |
| 77061 | <1% | 692 | $10K | |
| 82947 | <1% | 5,610 | $10K | |
| 82465 | <1% | 2,658 | $10K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 46 | $10K |
| 86695 | <1% | 995 | $10K | |
| 82105 | <1% | 788 | $10K | |
| 82652 | <1% | 685 | $10K | |
| 0031A | <1% | 284 | $10K | |
| 87015 | <1% | 1,902 | $9K | |
| 84703 | <1% | 9,534 | $9K | |
| 80164 | <1% | 1,493 | $9K | |
| 85730 | <1% | 7,509 | $8K | |
| 83721 | <1% | 1,284 | $8K | |
| 87205 | <1% | 3,430 | $8K | |
| 81374 | <1% | 147 | $8K | |
| 86762 | <1% | 2,283 | $8K | |
| 87147 | <1% | 3,645 | $8K | |
| 81003 | <1% | 11,807 | $8K | |
| 82550 | <1% | 3,491 | $8K | |
| 72202 | <1% | 140 | $8K | |
| 86787 | <1% | 1,813 | $8K | |
| 82784 | <1% | 997 | $7K | |
| 86765 | <1% | 1,602 | $7K | |
| 0074A | <1% | 309 | $7K | |
| 93225 | <1% | 95 | $7K | |
| 86706 | <1% | 884 | $6K | |
| 72131 | <1% | 187 | $6K | |
| 0034A | <1% | 203 | $6K | |
| 83690 | <1% | 16,427 | $6K | |
| 70491 | <1% | 32 | $6K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 64 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,859 | $6K |
| 84481 | <1% | 602 | $5K | |
| 0003A | <1% | 166 | $5K | |
| 73590 | <1% | 326 | $5K | |
| 98968 | <1% | 122 | $5K | |
| 90686 | <1% | 291 | $5K | |
| 0111A | <1% | 131 | $5K | |
| 90837 | Psychotherapy session, about an hour | <1% | 82 | $5K |
| 86431 | <1% | 1,602 | $5K | |
| 82747 | <1% | 384 | $5K | |
| 98967 | <1% | 138 | $5K | |
| 84436 | <1% | 1,358 | $5K | |
| C9399 | Unclassified drugs or biologicals | <1% | 452 | $5K |
| 0081A | <1% | 209 | $5K | |
| 73090 | <1% | 176 | $4K | |
| 83525 | <1% | 484 | $4K | |
| 76870 | <1% | 82 | $4K | |
| 59025 | Fetal non-stress test | <1% | 56 | $4K |
| 90756 | <1% | 178 | $4K | |
| 10061 | <1% | 17 | $4K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 69 | $4K |
| 0154A | <1% | 98 | $4K | |
| 86617 | <1% | 404 | $4K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 133 | $4K |
| 86200 | <1% | 678 | $4K | |
| 29540 | <1% | 28 | $4K | |
| 29580 | <1% | 79 | $4K | |
| 84560 | <1% | 1,866 | $4K | |
| 84425 | <1% | 212 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 448 | $3K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 152 | $3K |
| 72070 | <1% | 68 | $3K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 28 | $3K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 311 | $3K |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 398 | $3K |
| 83002 | <1% | 257 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 287 | $3K |
| 82950 | <1% | 761 | $3K | |
| 74220 | <1% | 30 | $3K | |
| J3101 | Injection, tenecteplase, 1 mg | <1% | 414 | $3K |
| 0082A | <1% | 104 | $3K | |
| 0240U | <1% | 34 | $3K | |
| 86235 | <1% | 69 | $3K | |
| 0112A | <1% | 62 | $2K | |
| 93880 | <1% | 26 | $2K | |
| 82140 | <1% | 294 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,375 | $2K |
| 85380 | <1% | 5,625 | $2K | |
| 86141 | <1% | 906 | $2K | |
| 90656 | <1% | 119 | $2K | |
| 84134 | <1% | 278 | $2K | |
| 77336 | <1% | 29 | $2K | |
| 83020 | <1% | 1,101 | $2K | |
| 84156 | <1% | 1,369 | $2K | |
| 82150 | <1% | 1,757 | $2K | |
| 82565 | <1% | 2,639 | $2K | |
| 82668 | <1% | 187 | $2K | |
| 86735 | <1% | 162 | $2K | |
| 84100 | <1% | 2,061 | $2K | |
| 96367 | <1% | 50 | $2K | |
| 84484 | <1% | 25,219 | $2K | |
| 71101 | <1% | 201 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 78,312 | $2K |
| 82533 | <1% | 242 | $2K | |
| 82785 | <1% | 194 | $2K | |
| 87324 | <1% | 281 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 25 | $2K |
| 73560 | <1% | 66 | $2K | |
| 76881 | <1% | 12 | $1K | |
| 87040 | <1% | 2,997 | $1K | |
| 87449 | <1% | 278 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,388 | $1K |
| 87338 | <1% | 123 | $1K | |
| 83520 | <1% | 153 | $1K | |
| 90785 | <1% | 144 | $1K | |
| 82951 | <1% | 128 | $1K | |
| 73100 | <1% | 19 | $1K | |
| 84154 | <1% | 121 | $1K | |
| 70498 | <1% | 86 | $1K | |
| 81329 | <1% | 15 | $1K | |
| 87045 | <1% | 227 | $1K | |
| 82627 | <1% | 67 | $1K | |
| 81025 | <1% | 13,446 | $1K | |
| 97014 | <1% | 21 | $993.80 | |
| 86334 | <1% | 173 | $981.64 | |
| 82248 | <1% | 594 | $964.36 | |
| 84479 | <1% | 295 | $927.00 | |
| 83993 | <1% | 67 | $925.47 | |
| 84445 | <1% | 32 | $874.26 | |
| 94010 | <1% | 371 | $829.34 | |
| 72170 | <1% | 68 | $755.88 | |
| 87329 | <1% | 102 | $755.70 | |
| 87328 | <1% | 102 | $755.70 | |
| 80177 | <1% | 116 | $749.26 | |
| 87476 | <1% | 53 | $737.22 | |
| 99443 | <1% | 13 | $690.37 | |
| 86850 | <1% | 5,257 | $660.14 | |
| 80178 | <1% | 242 | $650.89 | |
| J3490 | Unclassified drugs | <1% | 37,318 | $614.47 |
| 0073A | <1% | 16 | $600.00 | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 59 | $532.56 |
| 0013A | <1% | 13 | $520.00 | |
| 87071 | <1% | 122 | $494.31 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $461.79 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,544 | $450.35 |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $450.01 |
| 82805 | <1% | 286 | $433.60 | |
| 86160 | <1% | 31 | $412.92 | |
| 87899 | <1% | 76 | $412.20 | |
| 12011 | <1% | 42 | $399.14 | |
| 88360 | <1% | 828 | $348.59 | |
| 84132 | <1% | 846 | $330.51 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 57 | $323.26 |
| 71100 | <1% | 56 | $315.63 | |
| 83615 | <1% | 261 | $309.69 | |
| 86901 | <1% | 5,312 | $303.88 | |
| 86225 | <1% | 27 | $301.76 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,158 | $292.67 |
| 84155 | <1% | 313 | $274.75 | |
| 90688 | <1% | 16 | $267.60 | |
| 12001 | <1% | 641 | $251.21 | |
| 74021 | <1% | 26 | $244.41 | |
| 87252 | <1% | 344 | $237.45 | |
| 86308 | <1% | 151 | $237.12 | |
| 84270 | <1% | 14 | $228.36 | |
| 80069 | <1% | 59 | $225.60 | |
| 87046 | <1% | 38 | $180.40 | |
| 85046 | <1% | 85 | $159.45 | |
| 83630 | <1% | 12 | $150.56 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,244 | $142.06 |
| 87184 | <1% | 72 | $138.39 | |
| 83605 | <1% | 4,907 | $134.00 | |
| 96376 | <1% | 3,792 | $125.90 | |
| 84520 | <1% | 2,224 | $125.53 | |
| 84450 | <1% | 160 | $123.48 | |
| 80143 | <1% | 1,995 | $113.28 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 392 | $112.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 349 | $104.00 |
| 87075 | <1% | 41 | $99.44 | |
| 82330 | <1% | 14 | $98.92 | |
| 80179 | <1% | 1,919 | $95.71 | |
| 88300 | <1% | 69 | $93.44 | |
| 87181 | <1% | 305 | $92.29 | |
| 90714 | <1% | 116 | $88.19 | |
| 97163 | <1% | 14 | $83.98 | |
| 80305 | <1% | 50 | $75.50 | |
| 87101 | <1% | 12 | $73.60 | |
| 91305 | <1% | 4,644 | $70.63 | |
| 82436 | <1% | 627 | $67.20 | |
| 87280 | <1% | 84 | $65.28 | |
| 82977 | <1% | 28 | $63.45 | |
| 88304 | <1% | 831 | $58.95 | |
| 82952 | <1% | 15 | $48.62 | |
| 87807 | <1% | 206 | $48.56 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,528 | $44.81 |
| 99001 | <1% | 825 | $39.52 | |
| 80051 | <1% | 28 | $33.50 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,735 | $31.38 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 10,566 | $29.29 |
| 91308 | <1% | 379 | $28.98 | |
| 87634 | <1% | 81 | $21.43 | |
| 84460 | <1% | 187 | $20.99 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,478 | $20.82 |
| 82374 | <1% | 628 | $17.38 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 2,067 | $12.96 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,534 | $11.80 |
| 84295 | <1% | 632 | $10.62 | |
| 82009 | <1% | 48 | $9.30 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,141 | $5.87 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 489 | $4.93 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 972 | $4.82 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,924 | $3.33 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,871 | $2.11 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,879 | $1.19 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,750 | $0.98 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 882 | $0.65 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 481 | $0.57 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,492 | $0.44 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,453 | $0.37 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,193 | $0.37 |
| 91300 | <1% | 23,689 | $0.07 | |
| 91312 | <1% | 1,365 | $0.04 | |
| 91307 | <1% | 8,921 | $0.04 | |
| 91306 | <1% | 3,068 | $0.03 | |
| 91301 | <1% | 4,972 | $0.02 | |
| 94729 | 0% | 1,939 | $0.00 | |
| 88312 | 0% | 1,376 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 2,900 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 5,497 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 523 | $0.00 |
| 87220 | 0% | 27 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 570 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 33 | $0.00 |
| J9999 | Not otherwise classified, antineoplastic drugs | 0% | 328 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,719 | $0.00 |
| 84112 | 0% | 31 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 214 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,647 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 882 | $0.00 |
| 91311 | 0% | 221 | $0.00 | |
| 97803 | 0% | 291 | $0.00 | |
| 91313 | 0% | 787 | $0.00 | |
| 81243 | 0% | 13 | $0.00 | |
| 36592 | 0% | 216 | $0.00 | |
| 93226 | 0% | 96 | $0.00 | |
| 76000 | 0% | 17 | $0.00 | |
| 90658 | 0% | 59 | $0.00 | |
| 90611 | 0% | 83 | $0.00 | |
| 88173 | 0% | 12 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 170 | $0.00 |
| 87210 | 0% | 28 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 20 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 119 | $0.00 |
| 29125 | 0% | 25 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 21 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 372 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 8,527 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 6,744 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 880 | $0.00 |
| 91303 | 0% | 471 | $0.00 | |
| 94618 | 0% | 550 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 90 | $0.00 |
| 64488 | 0% | 103 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 827 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 423 | $0.00 |
| 91315 | 0% | 98 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 602 | $0.00 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 346 | $0.00 |
| 95012 | 0% | 57 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 146 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 360 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 1,050 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 143 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 87 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 17 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 121 | $0.00 |
| 88311 | 0% | 57 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 22 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 835 | $0.00 |
| 12002 | 0% | 42 | $0.00 | |
| 97802 | 0% | 44 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 15 | $0.00 |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 0% | 23 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 24 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 19 | $0.00 |
| 81255 | 0% | 14 | $0.00 | |
| 80320 | 0% | 52 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 40 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHARMEL, PATRICK (PRESIDENT - CEO)